Traditional medicine often relies on static snapshots—a single blood test or a one-time biopsy—to diagnose disease. However, biology is inherently a dynamic system. As Chris Bakal argues in Dynamic systems, we are moving past "parts lists" of the cell toward high-resolution understanding of biological oscillations and noise. To capture these shifts, researchers are increasingly using longitudinal multi-omics: the concurrent collection of genomic, transcriptomic, proteomic, and metabolic data from the same individuals over time.
The Power of the Molecular Movie
The primary intuition behind this approach is that an individual serves as their own best control. By establishing a temporal molecular baseline, researchers can detect deviations that signal the onset of disease long before clinical symptoms appear.
In a landmark study on prediabetes, Wenyu Zhou, M. Reza Sailani, and colleagues at the Snyder Lab filmed what they called a "molecular movie" of the human body. By tracking 106 individuals over four years, they demonstrated in Longitudinal multi-omics of host–microbe dynamics in prediabetes how diverse biological layers—from the gut microbiome to the blood proteome—interact during respiratory infections and the transition to Type 2 Diabetes. This same team later used this high-dimensional data to show that human biology in California fluctuates between two distinct biological "seasons" rather than the traditional four, as detailed in Deep longitudinal multiomics profiling reveals two biological seasonal patterns in California.
Mapping Cancer Evolution and Resistance
In oncology, the challenge is not just identifying the tumor, but predicting how it will evolve under the selective pressure of treatment. Static biopsies often miss the "identity shifts" that drive drug resistance.
For example, Peter Horak and Joachim Weischenfeldt documented a case where prostate cancer escaped treatment not by mutating its original drivers, but by undergoing a dramatic phenotypic shift into an aggressive neuroendocrine state (Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance). Similarly, Eva Dazert and Tujana Boldanova found that liver cancer resistance is often driven by "dedifferentiation," where cells lose their specialized identity (Multi-omics of sorafenib responsiveness in HCC patients).
By using serial sampling, researchers can map these evolutionary trajectories:
- Early Red Flags: Jiguang Wang identified that MYC amplification at diagnosis can predict therapy-induced hypermutation in recurrent gliomas (MYC amplification at diagnosis drives therapy-induced hypermutation of recurrent glioma).
- Regulatory "Dark Matter": Rebecca J. Leeman‐Neill showed how noncoding mutations retarget super-enhancers to drive the progression of B cell lymphoma (Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression).
Real Time Monitoring of Therapeutic Response
Longitudinal profiling also reveals the disconnect between systemic signals and localized cellular changes. In the INSPIRE study, Derek Clouthier, S.Y. Cindy Yang, and Scott Lien found that while immunotherapy drugs might block targets in the blood immediately, it can take weeks to reach the tumor. Their work in An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) emphasizes that only intratumoral immune markers, captured through serial biopsies, effectively predict clinical success.
This strategy is now being applied to refine complex treatments:
- Breast Cancer: Barbara Pistilli and M.F. Mosele used longitudinal integration to track how immune signaling pathways upregulate early in treatment, providing a temporal signature of response (Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial).
- Priming the Environment: Adrienne G. Waks and Jingxin Fu mapped how short "run-in" phases of chemotherapy can prime the tumor microenvironment (Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial).
High Frequency Sensing for Critical Transitions
The most extreme application of this idea occurs when biological systems undergo rapid, life-threatening transitions. In the first cases of pig-to-human heart xenotransplantation, Eloi Schmauch and Brian Piening collected multi-omic samples every six hours. As reported in Integrative Multi-omic Profiling of Two Human Decedents Receiving Pig Heart Xenografts Reveals Strong Perturbations in Early Immune-Cell and Cellular Metabolism Responses, this high-frequency sensing identified metabolic failure and rejection signals that were entirely invisible to standard hospital pathology.
Whether tracking the long-term effects of a BCG vaccine on "trained immunity" (Cancan Qi, Epigenetic Reprogramming Mediates Monocyte and Heterologous T Cell-derived Cytokine Responses after BCG Vaccination) or the molecular landscape of early rheumatoid arthritis (John D. Isaacs, RA-MAP), the shift toward longitudinal multi-omics represents a move from reactive to proactive medicine. By watching the "movie" of human biology, researchers can intervene at the exact moment the plot begins to turn.